Bacteromicsp. z o.o.
Other research and experimental development on natural sciences and engineering
Overview
Bacteromic is a diagnostic system that focuses on determining antibiotic susceptibility using microfluidic technology. It addresses the global issue of antibiotic resistance by providing phenotypic assessments of antibiotic effectiveness. The system aims to combat multidrug resistance, which poses significant challenges in modern medicine.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2017-03-30. Active
02 2490 0005 0000 4520 3307 9505- 27 2490 0005 0000 4600 2743 0667
- 45 2490 0005 0000 4600 3685 2923
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
7 public aid cases recorded, with a total value of $680,510.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Mar 17, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $41$41 | Marszałek Województwa Mazowieckiego | |
| Jun 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $5,993$5,993 | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $7,991$7,991 | Prezes Zakładu Ubezpieczeń Społecznych |
European Funds
4 projects recorded: 3 from FE lists ($1,130,513) and 1 Commission grant (FTS) ($2,156,328).
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2019-08-01 | 881101 - Bacteromic - intelligence for precision therapies against antimicrobial resistance: the first diagnostic panel that probes all the clinically relevant antibiotics at once | $2.2M$2,156,328 | 1.1.31 - Horizon 2020 | |
| 2018-06-01 | Uzyskanie międzynarodowej ochrony patentowej wynalazku "Metoda szybkiego wykrywania wzrostu bakterii" | $53,523$53,523 | Program Operacyjny Inteligentny Rozwój | |
| 2018-05-01 | Uzyskanie międzynarodowej ochrony patentowej wynalazków "Chip mikroprzepływowy" oraz "Segment inkubacyjny" | $98,564$98,564 | Program Operacyjny Inteligentny Rozwój |
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
In the case of a one-person management board, the company shall be represented by the sole member of the management board acting independently. In the case of a multi-member management board, the company shall be represented by two members of the management board acting jointly, or one member of the management board jointly with a commercial proxy.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 742,100 | $10,022,960.56 | 100% |
Beneficial owners
| Person | Rights | |
|---|---|---|
Piotr Garstecki (51)  | Na podstawie art. 2 ust.2 pkt 1 tiret 5 ustawy z dnia 1 marca 2018 r. o przeciwdziałaniu praniu brudnych pieniędzy i finansowaniu terroryzmu, z uwagi na brak możliwości ustalenia beneficjenta rzeczywistego- osoba fizyczna zajmująca wyższe stanowisko kierownicze (prezes zarządu) | |
Marcin Izydorzak (52) | Na podstawie art. 2 ust.2 pkt 1 tiret 5 ustawy z dnia 1 marca 2018 r. o przeciwdziałaniu praniu brudnych pieniędzy i finansowaniu terroryzmu, z uwagi na brak możliwości ustalenia beneficjenta rzeczywistego- osoba fizyczna zajmująca wyższe stanowisko kierownicze (członek zarządu) | |
Szymon Michał Ruta (51) | Na podstawie art. 2 ust.2 pkt 1 tiret 5 ustawy z dnia 1 marca 2018 r. o przeciwdziałaniu praniu brudnych pieniędzy i finansowaniu terroryzmu, z uwagi na brak możliwości ustalenia beneficjenta rzeczywistego- osoba fizyczna zajmująca wyższe stanowisko kierownicze (członek zarządu) |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| BiocamS.A. | $327,799.68 | biocam.ai | ||
| Phage Consultantssp. z o.o. | $193,130.82 | phageconsultants.com | ||
| ModicaP.S.A. | $103,400.72 | modica.bio | ||
| Microbe Plussp. z o.o. | $104,197.26 | microbe-plus.com | ||
| AM Lab Solutionssp. z o.o. | $100,896.70 | amsolutions.pl | ||
| GenomtecS.A. | $54,746.36 | genomtec.com | ||
| Advanced Diagnostic Equipmentsp. z o.o. | $43,171.56 | adediabetics.pl | ||
| Micropurasp. z o.o. | $12,556.50 | micropura.eu | ||
| Detoxedsp. z o.o. | $11,972.37 | detoxed.pl |
Change history
| Date | Event | |
|---|---|---|
| 2026-05-15 | Share capital change (35,105,000.00 PLN → 37,105,000.00 PLN) | |
| 2025-10-28 | Share capital change (34,105,000.00 PLN → 35,105,000.00 PLN) | |
| 2025-06-02 | Share capital change (33,105,000.00 PLN → 34,105,000.00 PLN) | |
| 2024-11-25 | Share capital change (32,105,000.00 PLN → 33,105,000.00 PLN) | |
| 2024-04-02 | Share capital change (29,105,000.00 PLN → 32,105,000.00 PLN) |
FAQ
Last updated: 2026-05-15